Half-Dose Radiopharmaceutical in Wide Beam Reconstruction

• Status: Terminated
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is recruiting patients already scheduled for a single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) test. SPECT-MPI is a nuclear imaging technique that uses a radioactive substance, or radiotracer, and special equipment to create three-dimensional (3D) images of the heart. Radiotracer is a radioactive dye that will make the structures of the heart visible and is routinely used to view blood flow in the heart, scan for damaged heart tissue, or assess heart function.

For a routine SPECT-MPI test, the radiotracer is given in one dose at the beginning of the test, followed by taking resting images of the heart. For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Participants will receive the same amount of radioactive material that would normally be given for this test; however, it will be administered in two half-doses. Participation in this study will add about 30 minutes to the time it takes to complete the routine test. The investigators expect to enroll about 160 subjects in this study at Northwestern.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Edwin Wu
• Collaborator: Astellas Pharma Global Development, Inc.
• Treatments: Radiopharmaceuticals; Technetium Tc 99m Sestamibi

Criteria

Inclusion Criteria:

• Patients over the age of 18 years

• Undergoing nuclear stress testing

• History of myocardial infarction, cardiomyopathy, heart failure or prior nuclear studies with resting perfusion defects

Exclusion Criteria:

• Unwilling or unable to undergo an additional resting SPECT acquisition

• Clinical contraindications to nuclear stress testing including acute myocardial infarction

• For patients undergoing exercise treadmill stress testing:

• Left bundle branch block or artificial ventricular pacemaker

• For patients undergoing regadenoson (Lexiscan) stress testing:

• Moderate to severe chronic obstructive pulmonary disease or asthma, second- or third degree atrioventricular block or sinus node disease (unless patients have a functioning artificial pacemaker), known hypersensitivity to aminophylline or adenosine

• Inability to give informed consent